Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Suspect foreigh money was mostly involved, probably USA.
Sp gained 10% Monday, then 16.67% yesterday.
Now down 9.52%. Will be interesting after about 1pm today!
The likes of Astrazeneca clearly need a way to more easily obtain the HER2 status of cancers that can be targeted if they are HER2 positive. This is what Angle in collaboration with Bioview are aiming for from a simple blood test.
All IMHO.
Up 6.35%.
LOL!
Davey50.
10% yesterday, now 16.67% today.
The market must think that the contract with Bioview to create a system whereby the Angle Parsortix machine catches circulating tumour cells that are then tested by the Biowiew automated A.I system to get their HER2 status could me a gold mine. I remember Mr Newland said Angle and Bioview would be open to having a pharma partner join them at the right time. Hmm........ Astrazeneca seem to be in need of a way to monitor cancer patients HER2 status.......... As do a shed load of others.
Al IMHO.
Up 16.67%.
Must be the Bioview news yesterday...................... I presume.
LOL!.
I see you have met.
Up 14.81%
Up 12.96.
Bid?
Nah.......... Hmm............ Astrazeneca maybe?????????????????
Up again - 11.11%!!
Up 9.26%
Up 7.41%.
news yesterday when the sp went up 10%.
Todays it's currently up another 7.4%.
Monitoring the HER2 status of cancers is but one way the Parsortix machine will be a winner.
You only have to read some of the recent Astrazenica RNS's to find out about HER2.
All IMHO.
Up 7.41%.
TwoGood2Die. I bet you are very pleased as you hold some apparently.
Daytraders?
Up 5.5%. Big trades coming in now.
3.7% up now.
so this might be the start of a more prolonged rise.
Which is exactly what Angle Plc are working on with Bioview:-
Astrazeneca RNS of 8th April:-
"Enhertu approved in the US as first tumour-agnostic HER2-directed therapy
for previously treated patients with metastatic HER2-positive solid tumours"
https://www.lse.co.uk/rns/AZN/enhertu-approved-in-us-for-her2-solid-tumours-d992ucbs0xpl3ik.html
Astrazeneca RNS of 2nd April:-
"Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer"
https://www.lse.co.uk/rns/AZN/fda-accepts-dato-dxd-bla-for-breast-cancer-6gb18korpqpp8bb.html
Market...... They need it IMHO.
Blubay
"What is the business scenario in which this would be "5p by end of April"?".
======================
One with similar odds to winning the lottery?
For my shares". LOL!
Posts. It's really quite amusing.
We will see......